Larixyl acetate

Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction[1][2][3][4][5].

Product Specifications

CAS Number

[4608-49-5]

UNSPSC

12352211

Target

Akt; Apoptosis; Autophagy; HPV; PERK; Src; TRP Channel

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Infection; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/larixyl-acetate.html

Concentration

10mM

Purity

99.46

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(CCC1)(C)[C@]([C@@]1(C)[C@H]2CC[C@](C)(O)C=C)([H])[C@@H](OC(C)=O)CC2=C

Molecular Formula

C22H36O3

Molecular Weight

348.52

References & Citations

[1]Urban N, et al. Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor. Mol Pharmacol. 2016 Jan;89 (1) :197-213. |[2]Chen X, et al. The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction. J Neuroinflammation. 2019 Jan 31;16 (1) :21.|[3]Wang J, et al. The analgesic action of larixyl acetate, a potent TRPC6 inhibitor, in rat neuropathic pain model induced by spared nerve injury. J Neuroinflammation. 2020 Apr 16;17 (1) :118.|[4]Jia M, et al. Larixyl acetate, a TRPC6 inhibitor, attenuates pressure overload‑induced heart failure in mice. Mol Med Rep. 2024 Mar;29 (3) :49.|[5]Liao HR, et al. Larixol inhibits fMLP-induced superoxide anion production and chemotaxis by targeting the βγ subunit of Gi-protein of fMLP receptor in human neutrophils. Biochem Pharmacol. 2022 Jul;201:115091.